These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8093316)

  • 1. Provocation paralysis.
    Wyatt HV
    Lancet; 1993 Jan; 341(8836):61-2. PubMed ID: 8093316
    [No Abstract]   [Full Text] [Related]  

  • 2. Provocation paralysis.
    Eggers HJ; Weyer J
    Lancet; 1993 Jan; 341(8836):62. PubMed ID: 8093318
    [No Abstract]   [Full Text] [Related]  

  • 3. Attributable risk of DTP (diphtheria and tetanus toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman.
    Sutter RW; Patriarca PA; Suleiman AJ; Brogan S; Malankar PG; Cochi SL; Al-Ghassani AA; el-Bualy MS
    J Infect Dis; 1992 Mar; 165(3):444-9. PubMed ID: 1538150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flawed immunisation policies in India led to polio paralysis.
    Mudur G
    BMJ; 1998 Apr; 316(7140):1264. PubMed ID: 9599049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injections and poliomyelitis: what are the risks of vaccine associated paralysis?
    Wyatt HV
    Dev Biol Stand; 1986; 65():123-6. PubMed ID: 3549394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Did India have the world's largest outbreak of poliomyelitis associated with injections of adjuvanted DPT?
    John TJ
    Indian Pediatr; 1998 Jan; 35(1):73-5. PubMed ID: 9707912
    [No Abstract]   [Full Text] [Related]  

  • 7. Poliomyelitis in a family with occurrence of localized paralysis after inoculation with combined diphtheria, pertussis, tetanus vaccine.
    NEVA FA
    Pediatrics; 1956 Jul; 18(1):59-63. PubMed ID: 13335321
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
    Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
    Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of diphtheria-tetanus-pertussis vaccine as an inflammatory and localizing agent.
    ZIEGLER J; KLEIN M
    AMA Am J Dis Child; 1953 Nov; 86(5):642; discussion, 642-4. PubMed ID: 13103787
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunological effect of simultaneous administration of poliomyelitis and combined diphtheria-tetanus-pertussis vaccines. II. Effect of combined diphtheria-tetanus-pertussis vaccine on immunological activity of Sabin's monovalent poliomyelitis vaccine].
    KELEMEN G; MAROCZI J; PACSA S; RETHY L
    Orv Hetil; 1961 Feb; 102():249-50. PubMed ID: 13752245
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R; Galtier F; Richard P; Baudin M
    Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of booster vaccinations against diphtheria, tetanus, pertussis and poliomyelitis.
    Gabutti G
    J Prev Med Hyg; 2008 Mar; 49(1):47-54. PubMed ID: 18792533
    [No Abstract]   [Full Text] [Related]  

  • 16. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on a combined diphtheria-pertussis-tetanus-poliomyelitis vaccine.
    SCHUCHARDT LF; MUNOZ J; VERWEY WF
    Am J Public Health Nations Health; 1960 Mar; 50(3 Pt 1):321-8. PubMed ID: 14443689
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
    Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Sri Lankan infant with vaccine associated acute flaccid paralysis.
    Perera P; Mettananda S
    Ceylon Med J; 2012 Mar; 57(1):42-3. PubMed ID: 22453711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.